Vinge advises EQT in connection with the acquisition of leading global pest control specialist Anticimex which becomes the first investment of EQT’s new purpose-driven strategy with longer-term investments and impact at its core.

Anticimex is a modern service company working with pest control, food safety, damp control, house inspections and fire protection. Anticimex has since 1934 developed from being a Swedish family business to an international company with over 4,500 employees in 17 countries. The transaction, where the selling party is the EQT VI fund, has an enterprise value of SEK 60 billion and the investment is made together with several long-term investors, such as Melker Schörling AB (MSAB), who will be the second largest shareholder, GIC, AMF, Interogo Holding Long-Term Equity and Alecta.

Vinge’s team consists of Christina Kokko and Peter Sundgren together with Maria Dahlin Kolvik, Ellinor Wargenbrant, Manne Bergström and Nando Basic (M&A/Corporate), Louise Brorsson Salomon, Seyran Sahin, Karl-Gustaw Tobola and Axel Jansson (Banking and Finance), Viveka Classon, Paulina Malmberg and David Lundahl (Corporate Insurance), Emma Stuart-Beck, Caroline Krassén and Elias Bohlin (Financial Services), Sofia Bergenstråhle (IPR), Isabell Nielsen (Commercial Agreements), Elin Broman (Employment), Lina Österberg and Ulf Pyk (Real Estate and Environment), Mika Jordan (IT), Nicklas Thorgerzon (GDPR) and Jessica Öijer (VDR). Partner Marcus Glader together with Emma Johansson and Johan Wahlbom advice in relation to merger filing.

Related

Vinge has advised Course Corrected VC on the establishment of Course Corrected VC Fund II

Vinge has advised Course Corrected VC on the establishment and structuring of their second fund, Course Corrected VC Fund II (the “Fund”).
November 12, 2026

Vinge advises Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun

Vinge is advising Svenska Handelsfastigheter in connection with the acquisition of the Tallen retail park in Falun from Dalafast. The acquisition comprises four properties with a total of 23,200 square metres of retail space, which together constitute Tallen’s largest retail area.
November 11, 2026

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026